Merck and Threshold Announce Global Agreement to Co-Develop and Commercialize Phase III Hypoxia-Targeted Drug TH-302
Merck KGaA announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold’s small molecule hypoxia-targeted drug.
Merck to Raise Donation Tenfold to Eliminate Worm Disease
Merck KGaA announced that in cooperation with the World Health Organization (WHO) it wants to eliminate the tropical worm disease schistosomiasis in Africa. The major offensive in this effort is Merck’s commitment to a tenfold...
Blood Test Instead of Biopsy Identifies Liver Damage
Siemens is marketing the first rapid, automated biomarker test for diagnosing and assessing liver fibrosis. The ELF test (Enhanced Liver Fibrosis test) takes approximately one hour to complete and requires only a blood sample.
Merck Receives European Approval to Expand Use of Rebif in Patients with Early Multiple Sclerosis
Merck KGaA announced that that the European Commission (EC) has approved extension of the indication of Rebif® (interferon beta-1a), Merck’s leading treatment for relapsing forms of multiple sclerosis (MS).
Fusion of Images: CT and Ultrasound Combined
The new ACUSON S3000* ultrasound system from Siemens will be able to display pictures from different imaging technologies at the same time. It includes advanced automated ultrasound fusion imaging. This feature provides...